Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)

NCT04146051 is registered in ClinicalTrials.gov with Cartesian Therapeutics as lead sponsor.

NCT NCT04146051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04146051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
Lead sponsor
Cartesian Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 4, 2019
Completion date
September 30, 2026
Enrollment
30 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized